Compared with liposomal MTO, the immune response was significantly enhanced by co-delivery an IDO-1 inhibitor in IDO-overexpressed cancers, such as renal cancer (RENCA) and breast cancer (4T1 and EMT6) [67]. Here, IDO1 is linked to breast carcinoma.